REX INTERNATIONAL HOLDING LIMITED Rex International Holding Limited announced the appointment of three new directors to its Board as part of its Board renewal process. The new directors are: Ms. Mae Heng, Independent Non-Executive Director and chairman of the Audit Committee; Mr. John d'Abo, Independent Non-Executive Director and member of the Nominating and Remuneration Committees; and Dr. Mathias Lidgren, Non-Independent Non- Executive Director and member of the Nominating Committee. The appointments will be effective from 4 May 2022.
Ms. Mae Heng has over 18 years of experience working at Ernst & Young Singapore. She is an Independent Non-Executive Director of Novo Tellus Alpha Acquisition, Grand Venture Technology Limited, Chuan Hup Holdings Limited, HRnetGroup Limited, Ossia International Limited and Apex Healthcare Berhad, and is chairman or a member of these companies' various board committees. Ms. Heng also holds directorships in her family-owned investment holding companies.
She was also the former Audit Committee Chairman of an SGX-listed real estate developer, as well as an online travel company. She is a Fellow Chartered Accountant with the Institute of Singapore Chartered Accountants and an ASEAN Chartered Professional Accountant. Mr. John d'Abo has over 30 years of executive experience in global investment banks and associated businesses mainly in Southeast Asia, advising listed companies on fund raising in both equity and debt and corporate advisory, during which he established relationships with a wide array of companies and investors across multiple sectors.
His investment banking career of 23 years includes stints at Royal Bank of Canada Capital Markets (Hong Kong), Royal Bank of Scotland (Hong Kong), Credit Suisse (Hong Kong), CLSA Asia-Pacific Markets (Hong Kong and New York) and HSBC James Capel (London). He is the founder and current Director of Erland Advisors, and is also the Chief Operating Officer of Caviar Biotec, a bio-tech and food-tech company. Mr. d'Abo holds a Bachelor of Arts with joint honours in French and Spanish from the University of Bristol, United Kingdom.
Dr Mathias Lidgren will represent the interests of Limea Ltd., the controlling shareholder of the Company. He has been a practising medical doctor since 2013 and has worked for the National Health Service (NHS), United Kingdom, the Hôpitaux Universitaires de Genéve, Geneva, Switzerland, and the Sahlgrenska University Hospital, Gothenburg, Sweden. He is currently practising at Skane University Hospitals in Lund, Sweden, and is also a post-doctoral researcher in the Division of Molecular Medicine and Gene Therapy, Department of Laboratory Medicine in Lund University, Sweden.
Dr. Lidgren currently holds directorships in Propatria AB, Rotationsplast i Munka-Ljungby AB, Caithness Fastighets AB, Forvaltningsaktiebolaget Maple, Trolleholms Slott AB, Captiosus AB and Strominnate Therapeutics AB; companies in Sweden involved in a range of businesses including real estate, manufacturing and medicine. Dr. Lidgren holds a Doctor of Philosophy in Health Economics from the Karolinska Institutet, Sweden, a Master of Arts in Genetics, as well as a medical degree (MB BChir) from the University of Cambridge, United Kingdom and a Bachelor of Science in Business Administration (BSBA) from the International University of Monaco. His medical degree is recognised by the Commission des professions médicales, Switzerland and Socialstyrelsen, Sweden.
He is licensed to practice medicine in the canton of Geneva, Switzerland and in Sweden. He is also a board-certified specialist in clinical genetics in Sweden.
